INONasdaqPharmaceutical PreparationsFiscal year ends December 31
INOVIO PHARMACEUTICALS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.00+0.01 (+1.00%)
Close on Oct 19, 2026
- Market cap
- $81.62M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
31.7%
33M of 103M shares
Institutional holders
102
23 new, 18 sold out
Net institutional buying
5M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Abigail P. Johnson | 9,339,614 | 13.50% | 13G (passive) amendment | Mar 31, 2026 |
| FMR LLC | 8,454,797 | 10.30% | 13G (passive) amendment | Jun 30, 2026 |
| Janus Henderson Group PLC | 6,666,295 | 9.99% | 13G (passive) amendment | Nov 28, 2025 |
| Highbridge Capital Management LLC | 6,190,475 | 8.20% | 13G (passive) amendment | Mar 31, 2026 |
| Robert Atchinson | 4,233,529 | 5.84% | 13G (passive) amendment | Mar 31, 2026 |
| Vanguard Capital Management | 4,161,566 | 5.05% | 13G (passive) | Jun 30, 2026 |
| Alyeska Investment Group, L.P. | 4,000,000 | 5.99% | 13G (passive) amendment | Dec 31, 2025 |
| Alyeska Fund GP, LLC | 4,000,000 | 7.53% | 13G (passive) | Sep 30, 2025 |
| Highbridge Capital Management, LLC | 3,633,333 | 9.20% | 13G (passive) | Dec 31, 2024 |
| RA Capital Healthcare Fund, L.P. | 10,666,523 | 9.90% | 13G (passive) | Jul 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of INO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 8,454,797 | 8.18% | $9.30M | −884,817 | 0.00% |
| Jupiter Topco LLC | 5,171,053 | 5.00% | $5.71M | New | 0.00% |
| Vanguard Capital Management LLC | 3,650,562 | 3.53% | $4.02M | +749,354 | 0.00% |
| Boxer Capital Management, LLC | 2,844,994 | 2.75% | $3.13M | +474,872 | 0.24% |
| ADAR1 Capital Management, LLC | 2,143,910 | 2.07% | $2.36M | +673,802 | 0.11% |
| D. E. Shaw & Co., Inc. | 1,351,656 | 1.31% | $1.49M | −861,163 | 0.00% |
| Two Sigma Investments, LP | 1,239,778 | 1.20% | $1.36M | +849,394 | 0.00% |
| Eversept Partners, LP | 1,035,360 | 1.00% | $1.14M | – | 0.06% |
| Geode Capital Management, LLC | 802,751 | 0.78% | $883.75K | +1,247 | 0.00% |
| Millennium Management LLC | 796,107 | 0.77% | $875.72K | −614,738 | 0.00% |
| BlackRock, Inc. | 779,057 | 0.75% | $856.96K | +116,876 | 0.00% |
| Vanguard Fiduciary Trust Co | 480,769 | 0.46% | $528.85K | +88,703 | 0.00% |
| Caption Management, LLC | 478,950 | 0.46% | $526.85K | New | 0.00% |
| Renaissance Technologies LLC | 361,339 | 0.35% | $397.47K | −282,438 | 0.00% |
| State Street Corp | 336,610 | 0.33% | $370.27K | +40,300 | 0.00% |
| Gsa Capital Partners Llp | 265,011 | 0.26% | $292 | −64 | 0.02% |
| UBS Group AG | 262,320 | 0.25% | $288.55K | +12,670 | 0.00% |
| Quadrature Capital Ltd | 258,928 | 0.25% | $284.82K | New | 0.00% |
| Citadel Advisors LLC | 241,775 | 0.23% | $265.95K | −44,577 | 0.00% |
| Northern Trust Corp | 174,394 | 0.17% | $191.83K | −124,476 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 102 | 33M | 31.7% | 23 / 27 | 15 / 18 | 10M | 5M |
| Q1 2026 | 99 | 31M | 30.3% | 16 / 19 | 23 / 15 | 5M | 4M |
| Q4 2025 | 101 | 33M | 31.9% | 20 / 25 | 22 / 18 | 16M | 4M |
| Q3 2025 | 99 | 21M | 20.1% | 24 / 21 | 28 / 28 | 14M | 4M |
| Q2 2025 | 103 | 10M | 10.0% | 24 / 23 | 29 / 28 | 2M | 5M |
| Q1 2025 | 107 | 14M | 13.2% | 18 / 33 | 27 / 13 | 3M | 3M |
| Q4 2024 | 104 | 13M | 12.9% | 26 / 34 | 14 / 20 | 5M | 1M |
| Q3 2024 | 98 | 9M | 8.3% | 21 / 26 | 20 / 16 | 3M | 1M |
| Q2 2024 | 96 | 8M | 7.8% | 31 / 21 | 18 / 21 | 5M | 1M |
| Q1 2024 | 87 | 4M | 4.1% | 83 / 1 | 3 / 3 | 4M | 0M |
| Q4 2023 | 7 | 0M | 0.0% | 7 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of INO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Small Cap Growth Fund | 6,993,661 | 6.76% | $4.73M | 0.05% | Jul 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 3,535,483 | 3.42% | $2.39M | 0.05% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 2,600,092 | 2.51% | $2.86M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 963,325 | 0.93% | $1.06M | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 348,001 | 0.34% | $455.88K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 280,138 | 0.27% | $308.15K | 0.02% | Jun 30, 2026 |
| Ultra-Small Company Fund | 173,000 | 0.17% | $190.30K | 0.19% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 104,005 | 0.10% | $136.25K | 0.00% | May 31, 2026 |
| Fidelity Series Total Market Index Fund | 96,119 | 0.09% | $125.92K | 0.00% | May 31, 2026 |
| Goldman Sachs Absolute Return Tracker Fund | 67,976 | 0.07% | $74.77K | 0.00% | Jun 30, 2026 |
| Vanguard Balanced Index Fund | 45,128 | 0.04% | $49.64K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 45,041 | 0.04% | $59.00K | 0.00% | May 31, 2026 |
| Vanguard Institutional Total Stock Market Index Fund | 42,017 | 0.04% | $46.22K | 0.00% | Jun 30, 2026 |
| Tiff Multi-Asset Fund | 21,590 | 0.02% | $23.75K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 18,882 | 0.02% | $20.77K | 0.01% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Jacqueline Elizabeth Shea | Chief Executive Officer, Director | 111,021 | 0.11% | May 21, 2026 |
| Peter Kies | CFO | 47,917 | 0.05% | May 21, 2026 |
| Laurent Humeau | Chief Scientific Officer | 48,986 | 0.05% | May 21, 2026 |
| Michael John Sumner | Chief Medical Officer | 42,038 | 0.04% | May 21, 2026 |
| Lota S. Zoth | Director | 8,726 | 0.01% | May 21, 2026 |
| Jay Shepard | Director | 9,209 | 0.01% | May 21, 2026 |
| Roger D. Dansey | Director | 8,916 | 0.01% | May 21, 2026 |
| Ann Calby Miller | Director | 9,877 | 0.01% | May 21, 2026 |
| Simon X. Benito | Director | 12,191 | 0.01% | May 21, 2026 |
| David B. Weiner | Director | 87,592 | 0.08% | May 21, 2026 |
| Wendy L. Yarno | Director | 10,512 | 0.01% | May 21, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael John Sumner Chief Medical Officer | May 20, 2026 | Tax withholding | −2,693 | $1.23 | $3.31K | 42,038 |
| Michael John Sumner Chief Medical Officer | May 20, 2026 | Option exercise | +9,450 | – | – | 44,731 |
| Peter Kies CFO | May 20, 2026 | Option exercise | +8,700 | – | – | 47,542 |
| Peter Kies CFO | May 20, 2026 | Tax withholding | −4,688 | $1.23 | $5.77K | 42,854 |
| Laurent Humeau Chief Scientific Officer | May 20, 2026 | Option exercise | +6,027 | – | – | 48,986 |
| Laurent Humeau Chief Scientific Officer | May 20, 2026 | Tax withholding | −2,163 | $1.23 | $2.66K | 46,823 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 20, 2026 | Tax withholding | −12,306 | $1.23 | $15.14K | 111,021 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 20, 2026 | Option exercise | +28,296 | – | – | 123,327 |
| Peter Kies CFO | May 15, 2026 | Option exercise | +4,771 | – | – | 41,413 |
| Peter Kies CFO | May 15, 2026 | Tax withholding | −2,571 | $1.30 | $3.34K | 38,842 |
| Michael John Sumner Chief Medical Officer | May 15, 2026 | Tax withholding | −680 | $1.30 | $884 | 35,281 |
| Michael John Sumner Chief Medical Officer | May 15, 2026 | Option exercise | +2,385 | – | – | 35,961 |
| Laurent Humeau Chief Scientific Officer | May 15, 2026 | Tax withholding | −1,712 | $1.30 | $2.23K | 42,959 |
| Laurent Humeau Chief Scientific Officer | May 15, 2026 | Option exercise | +4,771 | – | – | 44,671 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2026 | Option exercise | +17,744 | – | – | 102,748 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2026 | Tax withholding | −7,717 | $1.30 | $10.03K | 95,031 |
| Michael John Sumner Chief Medical Officer | Mar 31, 2026 | Option exercise | +4,292 | – | – | 34,799 |
| Michael John Sumner Chief Medical Officer | Mar 31, 2026 | Tax withholding | −1,223 | $1.74 | $2.13K | 33,576 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Option exercise | +5,010 | – | – | 22,860 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Option exercise | +11,550 | – | – | 34,410 |
| Michael John Sumner Chief Medical Officer | Feb 26, 2026 | Tax withholding | −3,903 | $1.79 | $6.99K | 30,507 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Option exercise | +7,366 | – | – | 42,934 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Tax withholding | −2,064 | $1.79 | $3.69K | 35,568 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Option exercise | +5,010 | – | – | 37,632 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2026 | Tax withholding | −3,034 | $1.79 | $5.43K | 39,900 |
| David B. Weiner Director | Feb 26, 2026 | Option exercise | +972 | – | – | 87,592 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Tax withholding | −8,057 | $1.79 | $14.42K | 70,260 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +28,401 | – | – | 98,661 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Tax withholding | −13,657 | $1.79 | $24.45K | 85,004 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | Feb 26, 2026 | Option exercise | +18,632 | – | – | 78,317 |
| Peter Kies CFO | Feb 26, 2026 | Tax withholding | −6,294 | $1.79 | $11.27K | 36,642 |
| Peter Kies CFO | Feb 26, 2026 | Option exercise | +5,010 | – | – | 35,267 |
| Peter Kies CFO | Feb 26, 2026 | Option exercise | +10,634 | – | – | 42,936 |
| Peter Kies CFO | Feb 26, 2026 | Tax withholding | −2,965 | $1.79 | $5.31K | 32,302 |
| Michael John Sumner Chief Medical Officer | Jun 30, 2025 | Option exercise | +2,916 | – | – | 17,850 |
| Simon X. Benito Director | May 21, 2025 | Option exercise | +2,167 | – | – | 12,191 |
| Ann Calby Miller Director | May 21, 2025 | Option exercise | +2,167 | – | – | 9,877 |
| Jay Shepard Director | May 21, 2025 | Option exercise | +2,167 | – | – | 9,209 |
| Wendy L. Yarno Director | May 21, 2025 | Option exercise | +2,167 | – | – | 10,512 |
| Roger D. Dansey Director | May 21, 2025 | Option exercise | +2,167 | – | – | 8,916 |
| David B. Weiner Director | May 21, 2025 | Option exercise | +2,167 | – | – | 86,620 |
| Lota S. Zoth Director | May 21, 2025 | Option exercise | +2,167 | – | – | 8,726 |
| Michael John Sumner Chief Medical Officer | May 15, 2025 | Option exercise | +2,385 | – | – | 15,614 |
| Michael John Sumner Chief Medical Officer | May 15, 2025 | Tax withholding | −680 | $1.95 | $1.33K | 14,934 |
| Peter Kies CFO | May 15, 2025 | Tax withholding | −2,566 | $1.95 | $5.00K | 30,257 |
| Peter Kies CFO | May 15, 2025 | Option exercise | +4,771 | – | – | 32,823 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2025 | Tax withholding | −7,717 | $1.95 | $15.05K | 59,685 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 15, 2025 | Option exercise | +17,744 | – | – | 67,402 |
| Laurent Humeau Chief Scientific Officer | May 15, 2025 | Tax withholding | −1,708 | $1.95 | $3.33K | 32,622 |
| Laurent Humeau Chief Scientific Officer | May 15, 2025 | Option exercise | +4,771 | – | – | 34,330 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 10, 2025 | Option exercise | +5,500 | – | – | 52,050 |
| Jacqueline Elizabeth Shea Chief Executive Officer, Director | May 10, 2025 | Tax withholding | −2,392 | $1.80 | $4.31K | 49,658 |
| David B. Weiner Director | Feb 26, 2025 | Option exercise | +972 | – | – | 84,453 |
| David B. Weiner Director | Feb 26, 2025 | Option exercise | +972 | – | – | 83,481 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Option exercise | +5,010 | – | – | 31,618 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Tax withholding | −2,059 | $1.98 | $4.08K | 29,559 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Option exercise | +3,855 | – | – | 28,192 |
| Laurent Humeau Chief Scientific Officer | Feb 26, 2025 | Tax withholding | −1,584 | $1.98 | $3.14K | 26,608 |
| Peter Kies CFO | Feb 26, 2025 | Tax withholding | −2,960 | $1.98 | $5.86K | 28,052 |
| Peter Kies CFO | Feb 26, 2025 | Option exercise | +5,010 | – | – | 31,012 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Zoth Lota Director | Jun 5, 2023 | 5,700 | $3.21K | Jun 5, 2023 | Restricted Stock |